National Engineering Research Center for Nanomedicine
With the rapid development of nanotechnology, nanodrugs have emerged as a key strategic direction with a revolutionary impact on the bio-pharmaceutical industry and the prospect of exponentially expanding markets.
On February 9th, 2009, the National Engineering Research Center for Nanomedicine (NERCN) was approved by the National Ministry of Science and Technology. NERCN was jointly established by multiple Schools and Departments of Huazhong University of Science and Technology including the School of Life Science and Technology, the School of Materials Science and Engineering, the School of Chemistry and Chemical Engineering, the School of Pharmacy, the School of Basic Medicine, Tongji Hospital, and Union Hospital and Wuhan Huazhong University Nano Pharmaceutical Co., LTD. Its main research interests focus on 1) Nanodrug formulation, 2) Nanotechnology for biomedical materials and diagnostic agents and 3) Engineering design and development for mass production of nanoproducts. It has already been one of the core platforms in the Biomedical Research Center of Wuhan Institute of Biotechnology in Biolake in Hubei Province and the Comprehensive New Drug Research and Development Center of the national “Major Drug Discovery Program”.
NERCN has a research team of more than 30 professors, 20 engineering technicians and 100 doctoral and master students working on drug development with a central administrative and management staff. It has 4,000 m2 and 2,000 m2 research and pilot-scale research space respectively and a variety of development facilities worth over 50 million RMB.
NERCN is currently in charge of the Major Scientific Research Project- “A new type of nanodrug therapy of liver cancer”. It has also participated in over 100 nationally and provincially funded projects including national special major technological project-“Major Drug Discovery”, national “973” projects, national major scientific and technological research projects, national “863” projects, national technological breakthrough/support programs, NSFC projects, provincial science and technology major breakthrough projects and enterprise cooperation projects. It has published more than 300 SCI papers and 3 books on nanomedicine. NERCN has over fifty Chinese and international authorized patents，three 1st prizes of provincial science and technology progress，and one 1st prize of natural science. Moreover, NERCN has 3 new drug licenses, 5 clinical trial approvals and over 10 drug production approvals.
By adhering to the concept of “innovation, sincerity, opening and collaboration”, NERCN has implemented a policy of innovative ideas, talented personnel and nano-industrialization. Under the guidance of this policy, NERCN will have a research team on both innovation and industrialization to achieve cutting-edge development in nanodrugs for the need of biomedical industry.
Address: Building B4, No. 666 Gaoxin Ave. East Lake High-tech Development Zone, Wuhan, Hubei, P. R. China
Post code: 430075
Contact: Mr. Yang Xiangliang